Srikanthan Meera A, Humbert Olivier, Haworth Kevin G, Ironside Christina, Rajawat Yogendra S, Blazar Bruce R, Palchaudhuri Rahul, Boitano Anthony E, Cooke Michael P, Scadden David T, Kiem Hans-Peter
Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Seattle Children's Hospital, Seattle, WA, USA.
Mol Ther Methods Clin Dev. 2020 Feb 8;17:455-464. doi: 10.1016/j.omtm.2020.02.001. eCollection 2020 Jun 12.
Conditioning chemotherapy is used to deplete hematopoietic stem cells in the recipient's marrow, facilitating donor cell engraftment. Although effective, a major issue with chemotherapy is the systemic genotoxicity that increases the risk for secondary malignancies. Antibody conjugates targeting hematopoietic cells are an emerging non-genotoxic method of opening the marrow niche and promoting engraftment of transplanted cells while maintaining intact marrow cellularity. Specifically, this platform would be useful in diseases associated with DNA damage or cancer predisposition, such as dyskeratosis congenita, Schwachman-Diamond syndrome, and Fanconi anemia (FA). Our approach utilizes antibody-drug conjugates (ADC) as an alternative conditioning regimen in an FA mouse model of autologous transplantation. Antibodies targeting either CD45 or CD117 were conjugated to saporin (SAP), a ribosomal toxin. knockout mice were conditioned with either CD45-SAP or CD117-SAP prior to receiving whole marrow from a heterozygous healthy donor. Bone marrow and peripheral blood analysis revealed equivalent levels of donor engraftment, with minimal toxicity in ADC-treated groups as compared with cyclophosphamide-treated controls. Our findings suggest ADCs may be an effective conditioning strategy in stem cell transplantation not only for diseases where traditional chemotherapy is not tolerated, but also more broadly for the field of blood and marrow transplantation.
预处理化疗用于清除受体骨髓中的造血干细胞,以促进供体细胞植入。尽管化疗有效,但化疗的一个主要问题是全身基因毒性,这会增加继发恶性肿瘤的风险。靶向造血细胞的抗体偶联物是一种新兴的非基因毒性方法,可打开骨髓微环境并促进移植细胞的植入,同时保持骨髓细胞数量完整。具体而言,该平台在与DNA损伤或癌症易感性相关的疾病中有用,如先天性角化不良、施-戴综合征和范可尼贫血(FA)。我们的方法在FA自体移植小鼠模型中利用抗体-药物偶联物(ADC)作为替代预处理方案。将靶向CD45或CD117的抗体与核糖体毒素皂草素(SAP)偶联。在从杂合健康供体接受全骨髓之前,用CD45-SAP或CD117-SAP对敲除小鼠进行预处理。骨髓和外周血分析显示供体植入水平相当,与环磷酰胺治疗的对照组相比,ADC治疗组的毒性最小。我们的研究结果表明,ADC可能是干细胞移植中的一种有效预处理策略,不仅适用于无法耐受传统化疗的疾病,而且更广泛地适用于血液和骨髓移植领域。